Posted on 9/8/17
Verastem Beats The Odds
On Wednesday, Verastem (VSTM) defied the odds when it had reported positive phase 3 results for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic . . .
Posted on 9/6/17
Teva Receives FDA Approval, But It Won't Be Enough
Recently, Teva (TEVA) received FDA approval for Austedo, which is a drug used to treat a movement disorder known as tardive dyskinesia. The problem is that . . .
Posted on 8/31/17
Immunogen Inks Jazz Deal: Moves To Push Tech To Limits
On Tuesday, Immunogen (IMGN) announced that it had inked a partnership deal with Jazz Pharmaceuticals (JAZZ). This partnership will allow Jazz to help develop Immunogen's anti-body . . .
Posted on 8/21/17
Pfizer Looks To Sneak In the Market Before Heavy Hitters
On Thursday, Pfizer (PFE) received FDA approval for its drug Besponsa to treat patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). This is a . . .
Posted on 8/17/17
Bristol-Myers Squibb Combination Treatment Not At The End Of The Crossroad
Bristol-Myers Squibb (BMY) announced results for its combination treatment treating patients with metastatic renal cell carcinoma (kidney cancer). The company reported mixed results in after-hours trade . . .
Posted on 8/8/17
Johnson & Johnson Receives Massive 'No' From Panel: Hope Left?
Recently, Johnson and Johnson (JNJ) drug sirukumab was voted down in an advisory panel. The panel recommended against approval by an overwhelming majority. The main issue . . .
Posted on 8/8/17
Pfizer Highly Recommended By Panel, Time For FDA Showdown
Recently, Pfizer (PFE) received a positive recommendation from a panel for its psoriatic arthritis drug XELJANZ (tofacitinib). The FDA Arthritis Advisory Committee (AAC) voted 10 to . . .
Posted on 8/7/17
Teva Receives Big Blow On Generics Pricing
Recently, Teva Pharmaceutical (NYSE:TEVA) released its second-quarter earnings report. The report showed that the company missed on both its bottom-line and top-line of expectations. The root . . .
Posted on 7/27/17
Pfizer Doesn't Want To Be Left In the Dust Of Avastin Biosimilar
Recently, Pfizer (PFE) announced it had achieved positive phase 3 results for its biosimilar candidate of Roche's (OTCQX:RHHBY) Avastin. Pfizer's biosimilar in question is known as . . .
Posted on 7/18/17
Johnson & Johnson: Approval Of TREMFYA Is Huge Win For Shareholders
Recently, the FDA approved Johnson & Johnson's (JNJ) treatment TREMFYA for patients with plaque psoriasis. That means Novartis (NVS), Eli Lilly (LLY), and Valeant Pharmaceuticals (VRX) . . .
Posted on 7/14/17
Pfizer Announces NDA Filing Acceptance By FDA For XELJANZ
Today, Pfizer (PFE) announced that its supplemental new drug application -- sNDA -- has been accepted for review by the FDA. The review will be on . . .
Posted on 7/7/17
Merck: Good Long-Term Despite Major Setback
On Wednesday, Merck (MRK) was notified by the FDA that it was hit with a clinical hold on three multiple myeloma studies that were treating patients . . .
Boston
